Disease · EFO_0004319

smoking cessation

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. smoking cessation. Diseases, record EFO_0004319. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/EFO_0004319

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: smoking cessation; Open Targets
Open Targets ID: EFO_0004319; Open Targets
MeSH: D016540; MeSH
NCI Thesaurus: C17427; NCI Thesaurus
Highest stage of its drugs: Phase 3, for 7 of its 30 drugs, from ClinicalTrials.gov; Open Targets

Drugs30

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
NICOTINE	CHEMBL3	Small molecule	Phase 3	ClinicalTrials.gov	76	76	74	Drugs and targets
(+/-)NICOTINE	CHEMBL440464	Small molecule	Phase 3	ClinicalTrials.gov	70	70	69	Drugs and targets
VARENICLINE	CHEMBL1076903	Small molecule	Phase 3	ClinicalTrials.gov	44	44	44	Drugs and targets
BUPROPION	CHEMBL894	Small molecule	Phase 3	ClinicalTrials.gov	23	23	23	Drugs and targets
CYTISINICLINE	CHEMBL497939	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
RIMONABANT	CHEMBL111	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
SEMAGLUTIDE	CHEMBL2108724	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
LORCASERIN	CHEMBL360328	Small molecule	Phase 2/3	ClinicalTrials.gov	3	3	3	Drugs and targets
METYRAPONE	CHEMBL934	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets
OXAZEPAM	CHEMBL568	Small molecule	Phase 2/3	ClinicalTrials.gov	2	2	2	Drugs and targets

1 to 10 of 30

See all 30 drugs

Targets58

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
CHRNA4	Neuronal acetylcholine receptor; alpha4/beta2	5	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist	Phase 3	https://conductscience.org/library/genes/1137	Drugs and targets
CHRNB2	Neuronal acetylcholine receptor; alpha4/beta2	5	Neuronal acetylcholine receptor; alpha4/beta2 agonist; Neuronal acetylcholine receptor; alpha4/beta2 partial agonist	Phase 3	https://conductscience.org/library/genes/1141	Drugs and targets
GABRA1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2/3	https://conductscience.org/library/genes/2554	Drugs and targets
GABRA2	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2/3	https://conductscience.org/library/genes/2555	Drugs and targets
GABRA3	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2/3	https://conductscience.org/library/genes/2556	Drugs and targets
GABRA4	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2/3	https://conductscience.org/library/genes/2557	Drugs and targets
GABRA5	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2/3	https://conductscience.org/library/genes/2558	Drugs and targets
GABRA6	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2/3	https://conductscience.org/library/genes/2559	Drugs and targets
GABRB1	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2/3	https://conductscience.org/library/genes/2560	Drugs and targets
GABRB2	GABA-A receptor; anion channel	3	GABA-A receptor; anion channel positive allosteric modulator; GABA-A receptor; anion channel positive modulator	Phase 2/3	https://conductscience.org/library/genes/2561	Drugs and targets

1 to 10 of 58

See all 58 targets

Trials138

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT00483002	Post Marketing Surveillance Study To Observe Safety And Efficacy Of Champix® Tablets		3,719	2012-05-11	Smoking Cessation	VARENICLINE	Its record names the disease	ClinicalTrials.gov
NCT00808015	ASIA CHOICES CHampix (Varenicline) Observational Investigation in the CEssation of Smoking		1,373	2011-07-28	Smoking Cessation	VARENICLINE	Its record names the disease	ClinicalTrials.gov
NCT01314001	Pharmacogenetics of Nicotine Addiction Treatment	Phase 3	1,246	2016-03-03	Nicotine Addiction	(+/-)NICOTINE, NICOTINE, VARENICLINE	Its record names the disease	ClinicalTrials.gov
NCT05206370	A Second Study of Cytisinicline for Smoking Cessation in Adult Smokers	Phase 3	792	2026-01-14	Smoking Cessation	CYTISINICLINE	Its record names the disease	ClinicalTrials.gov
NCT00282984	Efficacy and Safety of Varenicline in Smokers With Cardiovascular Disease Who Wish to Quit Smoking	Phase 3	714	2009-04-29	Smoking Cessation	VARENICLINE	Its record names the disease	ClinicalTrials.gov
NCT01303861	Concurrent Bupropion / Varenicline for Smoking Cessation	Phase 3	702	2014-08-01	Nicotine Dependence	(+/-)NICOTINE, BUPROPION, NICOTINE, VARENICLINE	Its record names the disease	ClinicalTrials.gov
NCT04525755	STARS (Smoking Treatment And Remote Sampling) Study	Phase 1/2	652	2026-02-17	Smoking, Smoking Cessation, Tobacco Smoking, Cigarette Smoking	(+/-)NICOTINE, NICOTINE, VARENICLINE	Its record names the disease	ClinicalTrials.gov
NCT00894166	Evaluation of a Tailored Smoking Cessation Treatment Algorithm Based on Initial Treatment Response and Genotype	Phase 3	606	2012-12-26	Smoking Cessation	(+/-)NICOTINE, BUPROPION, NICOTINE, VARENICLINE	Its record names the disease	ClinicalTrials.gov
NCT02044874	A Study to Evaluate the Effect of Lorcaserin Hydrochloride on Smoking Cessation	Phase 2	603	2019-04-16	Smoking Cessation	LORCASERIN HYDROCHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT02168855	Cessation in Non-Daily Smokers	Not applicable	505	2020-05-06	Smoking	(+/-)NICOTINE, NICOTINE	Its record names the disease	ClinicalTrials.gov

1 to 10 of 138

See all 138 trials

Comparisons in its trials109

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Varenicline (Var) vs Placebo (Pbo): Number of Responders With Continuous Abstinence (CA) Through Week 24	100 of 353	34 of 350	703	NCT00282984	Trial comparisons
Varenicline (Var) vs Placebo (Pbo): Number of Participants With a 4 Week Point Prevalence of Smoking Cessation	99 of 353	57 of 350	703	NCT00282984	Trial comparisons
Less Dependent vs More Dependent: serious adverse events	0 of 249	0 of 230	479	NCT00734617	Trial comparisons
Active Nicotine Gum vs Inactive Gum: Smoking Cessation, Continuous 6-month Abstinence	13 of 181	10 of 188	369	NCT02168855	Trial comparisons
Active Nicotine Gum vs Inactive Gum: deaths from any cause	0 of 181	0 of 188	369	NCT02168855	Trial comparisons
Active Nicotine Gum vs Inactive Gum: serious adverse events	9 of 181	14 of 188	369	NCT02168855	Trial comparisons
Extended Run-In vs Standard Run-In: Number of Participants With Continuous Abstinence at 6-Month Follow-Up as Assessed by Self-Report and Bio-verification	37 of 163	29 of 157	320	NCT03262662	Trial comparisons
Extended Run-In vs Standard Run-In: Number of Participants With Continuous Abstinence at End-of-Treatment (EOT) as Assessed by Self-Report and Bio-verification	64 of 163	57 of 157	320	NCT03262662	Trial comparisons
Arm I (Varenicline) vs Arm II (Nicotine Patch): deaths from any cause	0 of 200	0 of 100	300	NCT01771627	Trial comparisons
Arm I (Varenicline) vs Arm II (Nicotine Patch): serious adverse events	0 of 200	0 of 100	300	NCT01771627	Trial comparisons

1 to 10 of 109

See all 109 comparisons in its trials

Papers from its trials89

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
42096636	RESULT	1	PubMed
33761149	RESULT	1	PubMed
28500373	RESULT	1	PubMed
28498504	RESULT	1	PubMed
23603206	RESULT	1	PubMed
23074432	RESULT	1	PubMed
22417200	RESULT	1	PubMed
20707784	RESULT	1	PubMed
20542391	RESULT	1	PubMed
20207347	RESULT	1	PubMed

1 to 10 of 89

See all 89 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/EFO_0004319

GET https://conductscience.org/api/diseases/v1/EFO_0004319/drugs?page=2

API reference For AI assistants